港股異動 | 君實生物(688180.SH)高開6.24% 研究發現VV116在RSV多個敏感細胞繫上具有優異的抗病毒效果
格隆匯4月19日丨君實生物(688180.SH)高開6.24%,報53.6港元,總市值488億港元。該公司17日發佈公吿,由公司控股子公司上海君拓生物醫藥科技有限公司(“君拓生物”)與蘇州旺山旺水生物醫藥有限公司(“旺山旺水”)合作開發的口服核苷類抗SARS-CoV-2藥物VV116片在RSV 多個敏感細胞繫上具有優異的抗病毒效果。在小鼠模型上,VV116 具有較高的口服生物利用度、良好的組織分佈和顯著優於利巴韋林的抗病毒效果,且能緩解肺部組織的病理損傷情況。該研究為治療RSV 感染提供了有價值的臨牀候選藥物。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.